Work

Phase I study of TAK-285, an investigational HER2/EGFR inhibitor, in patients (pts) with advanced cancer: Updated results and assessment of human CSF distribution.

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.15_suppl.2538

Authors: E. G. Chiorean, E. A. Sausville, E. I. Heath, A. Weise, J. Gomez-Navarro, K. Venkatakrishnan, S. Sankoh, J. Wu, M. Corvez, P. LoRusso

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2564005606

Cites:

Cited by: 3

Related to: 10